Stockscreener 앱 받기
3.61
1.37%
-0.05
전일 마감가:
$3.66
열려 있는:
$3.44
하루 거래량:
8,205
Relative Volume:
0.36
시가총액:
$9.86M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+15.15%
1개월 성능:
+40.99%
6개월 성능:
-5.48%
1년 성능:
+0.00%
1일 변동 폭
$3.3145
$3.6871
1주일 범위
$3.12
$3.78
52주 변동 폭
$1.96
$6.60
Cosciens Biopharma Inc Stock (CSCI) Company Profile
CSCI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSCI
Cosciens Biopharma Inc
|
3.6871 | 9.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.09 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.32 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.34 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.61 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.06 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Cosciens Biopharma Inc 주식(CSCI)의 최신 뉴스
COSCIENS Biopharma Sets Date for Annual Meeting Amid Strategic Shifts - TipRanks
Fennec Pharmaceuticals: Top 10 Undervalued Biotechnology Industry Stocks (FRX) - The Globe and Mail
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
COSCIENS Biopharma appoints Anna Biehn as new CEO amid leadership change - N24.com.tr
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Bi - GuruFocus
COSCIENS Biopharma (CSCI) Names Anna Biehn as New CEO | CSCI Sto - GuruFocus
COSCIENS Biopharma names new CEO Anna Biehn By Investing.com - Investing.com Canada
COSCIENS Biopharma names new CEO Anna Biehn - Investing.com Australia
COSCIENS Biopharma names Anna Biehn as new CEO By Investing.com - Investing.com South Africa
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$1.89 loss in FY 2023) - simplywall.st
COSCIENS Biopharma names Anna Biehn as new CEO - Investing.com Australia
Cosciens Biopharma appoints Biehn as CEO - TipRanks
COSCIENS Biopharma Appoints Anna Biehn as New CEO to Drive Growth in Natural-Based Products - TipRanks
Cosciens Biopharma Appoints Anna Biehn as Chief Executive Officer - marketscreener.com
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer - The Manila Times
COSCIENS Biopharma Full Year 2024 Earnings: US$5.93 loss per share (vs US$13.64 loss in FY 2023) - Yahoo Finance
COSCIENS Biopharma Reports Revenue Growth and Strategic Repositioning - MSN
Cosciens Biopharma Charts New Path Following Ceapro Merger - Finimize
COSCIENS Biopharma reports Q4 and full year 2024 results - Investing.com Australia
COSCIENS Biopharma: Q4 Earnings Snapshot - CT Insider
COSCIENS Biopharma reports Q4 and full year 2024 results By Investing.com - Investing.com South Africa
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 202 - GuruFocus
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Natural Products Drive COSCIENS Growth: Revenue Jumps 35% as Pipeline Advances - Stock Titan
COSCIENS Biopharma Faces Management Cease Trade Order Amid Filing Delays - TipRanks
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Lelezard
COSCIENS Biopharma Faces Trading Halt: What Investors Need to Know - AInvest
Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports - Stock Titan
Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday? - Insider Monkey
COSCIENS Biopharma flags potential reporting delay By Investing.com - Investing.com Australia
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Sector Update: Health Care Stocks Edge Higher Late Afternoon -March 20, 2025 at 04:02 pm EDT - MarketScreener
Top Midday Decliners -March 20, 2025 at 02:10 pm EDT - MarketScreener
COSCIENS Biopharma flags potential reporting delay - Investing.com
COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger Complexities - TipRanks
Cosciens Biopharma Inc (CSCI) 재무 분석
Cosciens Biopharma Inc (CSCI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.60%
3.33%
자본화:
|
볼륨(24시간):